NCT00529087View on ClinicalTrials.gov

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

460

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Constipation
Interventions
DRUG

N-methylnaltrexone bromide (MOA-728)

Subcutaneous

OTHER

placebo

placebo

Trial Locations (78)

11023

Great Neck

11580

Valley Stream

21075

Elkridge

22304

Alexandria

23666

Hampton

24073

Christiansburg

27103

Winston-Salem

28204

Charlotte

30060

Marietta

30281

Stockbridge

30329

Atlanta

32174

Ormond Beach

32216

Jacksonville

32607

Gainesville

32626

Cheifland

32789

Winter Park

32806

Orlando

33180

Miami

33409

West Palm Beach

33458

Jupiter

33511

Brandon

33603

Tampa

33756

Clearwater

33770

Largo

34104

Naples

34471

Ocala

34474

Ocala

34609

Spring Hill

36606

Mobile

36608

Mobile

37404

Chattanooga

39531

Biloxi

39564

Ocean Springs

43623

Toledo

45439

Dayton

46123

Avon

46250

Indianapolis

49079

Paw Paw

49601

Cadillac

49684

Traverse City

50265

West Des Moines

59808

Missoula

59901

Kalispell

60115

DeKalb

60610

Chicago

65719

Nixa

68114

Omaha

70584

Sunset

71105

Shreveport

71913

Hot Springs

73112

Oklahoma City

75230

Dallas

75251

Dallas

76034

Colleyville

77701

Beaumont

78209

San Antonio

78229

San Antonio

78705

Austin

85351

Sun City

85710

Tucson

85741

Tucson

87102

Albuquerque

89119

Las Vegas

90048

Los Angeles

90716

Hawaiian Gardens

90813

Long Beach

92121

San Diego

92801

Anaheim

92843

Garden Grove

97210

Portland

97504

Medford

99204

Spokane

99208

Spokane

02115

Boston

02301

Brockton

27607-6475

Raleigh

19056-2404

Levittown

25304-1965

Charleston

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00529087 - Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain | Biotech Hunter | Biotech Hunter